BACKGROUND
Antithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory properties that is also known to attenuate acute inflammation, prevent ischemia-reperfusion injury, and disseminated intravascular coagulation (DIC) associated with sepsis and endotoxemia. Here, we examined the ability of AT-III to modify parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection (AR).
METHODS
After left single lung transplantations (BN-->Lew), recipient animals were treated i.v. with 50 U/kg of human AT-III (low dose group), 500 U/kg of human AT-III (high dose group), or normal saline (control group) on days 2 and 4 posttransplant. All animals were sacrificed on day 6, and several pathological categories of acute inflammation related to AR were scored (0-4). The effect of AT-III on concanavalin A (Con A)-stimulated rat spleen cell proliferation was also examined.
RESULTS
The stage of AR, and the degrees of edema, hemorrhage, and necrosis were significantly reduced in the high dose group compared with the control group. AT-III significantly inhibited rat spleen cell proliferation in response to Con A, in a dose-dependent manner. Maximal inhibition was seen at 15 U/ml in culture. Identical inhibition of Con-A-stimulated cultures occurred in both serum free and serum-containing media, indicating that AT-III inhibition of Con-A-stimulated rat spleen cell proliferation is independent of its actions on thrombin.
CONCLUSIONS
1) AT-III treatment significantly improves parameters of acute inflammation seen in a highly histoincompatible model of rat lung AR. 2) AT-III inhibits in vitro T cell proliferation to the potent mitogen Con A, suggesting that protease inhibition may inhibit T cell activation in vitro. 3). The beneficial effects of AT-III on parameters of lung AR relate to the anti-coagulant, anti-inflammatory, and possibly immunoregulatory actions of AT-III.
[1]
M. Uchiba,et al.
The Anti-Inflammatory Properties of Antithrombin III: New Therapeutic Implications
,
1998,
Seminars in thrombosis and hemostasis.
[2]
J. Imanishi,et al.
The anticoagulant effect of antithrombin III on hyperacute xenograft rejection.
,
1996,
Transplantation proceedings.
[3]
B. Griffith,et al.
Clinical trial of tacrolimus versus cyclosporine in lung transplantation.
,
1995,
The Annals of thoracic surgery.
[4]
P. Linsley,et al.
Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines.
,
1995,
Transplantation.
[5]
D. Altieri,et al.
Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation.
,
1994,
Cellular immunology.
[6]
C. Chopin,et al.
Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.
,
1993,
Chest.
[7]
W. Faulk,et al.
The endothelial heparan sulfate-antithrombin III natural anticoagulant pathway in normal and transplanted human kidneys.
,
1992,
Transplantation.
[8]
W. Faulk,et al.
Natural anticoagulant pathways in normal and transplanted human hearts.
,
1992,
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.